“…Compound 4g was the most effective one with IC 50 =0.00586 mM compared with Doxorubicin (IC 50 =0.00686 mM). This derivative was selected by US-NCI for more antitumor activity screening [30][31][32][33][34][35] The observed data expressed as GI 50 (the concentration resulting in a 50% growth inhibition of the tumor compared with the control experiments), TGI (the concentration resulting in a 100% growth inhibition of the tumor compared with the control experiments) and LC 50 were presented in Table 2. It showed promising activity against 38 cell lines especially, HOP-92, NCI-H226 (non-small cell lung cancer), GI 50 =0.000865, 0.00127 mM, respectively, SF-539, SNB-75 (CNS cancer), GI 50 =0.00144, 0.000811 mM, respectively, MALME-3M, SK-MEL-5 (melanoma), GI 50 =0.0016, 0.0015 mM, respectively, OVCAR-4, SK-OV-3 (ovarian cancer), GI 50 =0.00102, 0.00115 mM, respectively, 786-0, A498, RXF 393, UO-31 (renal cancer), GI 50 =0.00112, 0.00111, 0.00118, 0.00148 mM, respectively and MDA-MB-231/ATCC, HS 578T (breast cancer), GI 50 =0.00133, 0.00113 mM, respectively.…”